tafamidis + meglumine Oral solution 10 mg/ml , 20 mg/ml

This company is a contract development and manufacturing organization (CDMO) specializing in the production of high-potency and oncological oral liquid formulations. Established in recent years, the company operates primarily in the European Union and North America. Their core expertise lies in developing and manufacturing customized, high-quality, and cost-effective oral liquid products for patients requiring dose titration and tailored treatment plans. Their production lines focus on oncology, specifically targeting high-potency medications for oral administration. This CDMO has a strong emphasis on quality, with a state-of-the-art facility and robust quality systems. Their services encompass the entire drug development process from formulation and analytical development to clinical trials, regulatory support, and commercial manufacturing. This company is actively expanding its GMP-approved manufacturing facilities and strives to provide a full range of services to support partners in overcoming the unique challenges of developing high-potency oral liquid formulations.